A Reliable Research Partner in Life Science and Medicine

# Recombinant Mouse VEGFR3/FLT4 Protein (His Tag)

Catalog No. PKSM040596

*Note:* Centrifuge before opening to ensure complete recovery of vial contents.

### **Description**

**Synonyms** AI323512;Chy;Flt-4;VEGFR-3;VEGFR3

**Species** Mouse

Expression Host HEK293 Cells
Sequence Met 1-Glu 775
Accession P35917-1
Calculated Molecular Weight 86.4 kDa
Observed molecular weight 95-105 kDa
Tag C-His

Bioactivity Immobilized mouse VEGFR3-His at 10 μg/mL (100 μl/well) can bind mouse Fc-

VEGFD, The EC50 of mouse Fc-VEGFD is 44 ng/mL.

### **Properties**

**Purity** > 97 % as determined by reducing SDS-PAGE.

**Endotoxin** < 1.0 EU per μg of the protein as determined by the LAL method.

**Storage** Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to

-80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots

of reconstituted samples are stable at < -20°C for 3 months.

**Shipping** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation** Lyophilized from sterile PBS, pH 7.4


Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as

protectants before lyophilization.

Please refer to the specific buffer information in the printed manual.

**Reconstitution** Please refer to the printed manual for detailed information.

#### Data



> 97 % as determined by reducing SDS-PAGE.

### **Background**

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members

#### For Research Use Only

Toll-free: 1-888-852-8623 Tel: 1-832-243-6086 Fax: 1-832-243-6017

Web: www.elabscience.com

Email: techsupport@elabscience.com

## **Elabscience Bionovation Inc.**



A Reliable Research Partner in Life Science and Medicine

VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

For Research Use Only

Toll-free: 1-888-852-8623 Tel: 1-832-243-6086 Fax: 1-832-243-6017 Email: techsupport@elabscience.com

Web: www.elabscience.com